A detailed history of Voya Investment Management LLC transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 49,959 shares of ZNTL stock, worth $161,367. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,959
Previous 19,243 159.62%
Holding current value
$161,367
Previous $78,000 134.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.9 - $4.57 $89,076 - $140,372
30,716 Added 159.62%
49,959 $183,000
Q2 2024

Aug 14, 2024

SELL
$4.09 - $16.13 $512,804 - $2.02 Million
-125,380 Reduced 86.69%
19,243 $78,000
Q1 2024

May 15, 2024

SELL
$10.83 - $16.49 $45,832 - $69,785
-4,232 Reduced 2.84%
144,623 $2.28 Million
Q4 2023

Feb 14, 2024

BUY
$9.84 - $20.13 $381,329 - $780,097
38,753 Added 35.2%
148,855 $2.26 Million
Q3 2023

Nov 14, 2023

BUY
$19.63 - $28.29 $74,201 - $106,936
3,780 Added 3.56%
110,102 $2.21 Million
Q2 2023

Aug 14, 2023

BUY
$17.41 - $30.05 $1.54 Million - $2.66 Million
88,558 Added 498.53%
106,322 $3 Million
Q3 2022

Nov 14, 2022

BUY
$20.23 - $31.73 $69,833 - $109,531
3,452 Added 24.12%
17,764 $385,000
Q1 2022

May 16, 2022

BUY
$41.58 - $80.89 $12,141 - $23,619
292 Added 2.08%
14,312 $660,000
Q4 2021

Feb 14, 2022

BUY
$66.92 - $84.79 $15,123 - $19,162
226 Added 1.64%
14,020 $1.18 Million
Q3 2021

Nov 15, 2021

BUY
$46.83 - $73.5 $34,326 - $53,875
733 Added 5.61%
13,794 $919,000
Q2 2021

Aug 16, 2021

BUY
$37.41 - $62.25 $19,191 - $31,934
513 Added 4.09%
13,061 $695,000
Q1 2021

May 17, 2021

BUY
$35.69 - $52.72 $21,378 - $31,579
599 Added 5.01%
12,548 $544,000
Q4 2020

Feb 16, 2021

BUY
$31.71 - $57.97 $378,902 - $692,683
11,949 New
11,949 $621,000

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $184M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.